Glecaprevir

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

Glecaprevir (ABT 493;A 1282576) is a novel HCV NS3/4A protease inhibitor with pan-genotypic activity, inhibits NS3/4A proteases from HCV genotypes 1-6 in vitro with IC50 of 3.5-11.3 nM.

Glecaprevir (ABT 493;A 1282576) is a novel HCV NS3/4A protease inhibitor with pan-genotypic activity, inhibits NS3/4A proteases from HCV genotypes 1-6 in vitro with IC50 of 3.5-11.3 nM; inhibits the replication of stable HCV subgenomic replicons genotypes 1-6 with EC50 of 0.21-4.6 nM, has a median EC50 of 0.30 nM (0.05 - 3.8 nM) for HCV replicons containing proteases from 40 HCV genotype 1-5 samples; the combination of ABT-493 and ABT-530 demonstrates potent antiviral activity and acceptable safety in clinical trails with HCV genotype 1 infection.HCV Infection Phase 2 Clinical

ABT 493;A 1282576

Microbiology/Virology

HCV

HCVNS3/4Aprotease

Infection

HCV Infection

1365970-03-1

838.87

C38H46F4N6O9S

>98% (HPLC)

DMSO: 80 mg/mL （ < 1 mg/ml refers to the product slightly soluble or insoluble )

CC1(CC1)S(=O)(=O)NC(=O)C2(CC2C(F)F)NC(=O)C3CC4CN3C(=O)C(NC(=O)OC5CCCC5OCC=CC(C6=NC7=CC=CC=C7N=C6O4)(F)F)C(C)(C)C

(33R,35S,91R,92R,5S,E)-5-(tert-butyl)-N-((1R,2R)-2-(difluoromethyl)-1-(((1-methylcyclopropyl)sulfonyl)carbamoyl)cyclopropyl)-14,14-difluoro-4,7-dioxo-2,8,10-trioxa-6-aza-1(2,3)-quinoxalina-3(3,1)-pyrrolidina-9(1,2)-cyclopentanacyclotetradecaphan-12-ene-35

(-20℃)

With Ice Pack

≥ 2 years